Skip to main content

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tue Jan 6, 8:16AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Definitive Healthcare Corp (DHResearch Report) and Mettler-Toledo (MTDResearch Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Definitive Healthcare Corp (DH)

Stifel Nicolaus analyst David Grossman maintained a Buy rating on Definitive Healthcare Corp on January 2 and set a price target of $5.00. The company’s shares closed last Friday at $2.38.

According to TipRanks.com, Grossman is a 4-star analyst with an average return of 5.6% and a 51.7% success rate. Grossman covers the Technology sector, focusing on stocks such as International Business Machines, Automatic Data Processing, and Exlservice Holdings. ;'>

Definitive Healthcare Corp has an analyst consensus of Hold, with a price target consensus of $3.71, implying a 29.3% upside from current levels. In a report released today, Bank of America Securities also maintained a Buy rating on the stock with a $4.00 price target.

See the top stocks recommended by analysts >>

Mettler-Toledo (MTD)

In a report issued on January 2, Patrick B Donnelly from Citi maintained a Buy rating on Mettler-Toledo. The company’s shares closed last Friday at $1411.39.

According to TipRanks.com, Donnelly is a 4-star analyst with an average return of 4.3% and a 49.7% success rate. Donnelly covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Fortrea Holdings Inc. ;'>

Mettler-Toledo has an analyst consensus of Moderate Buy, with a price target consensus of $1502.11.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.